The patent expiration date for Tagrisso (osimertinib) in the United States is a key consideration for its market exclusivity.
When does Tagrisso's primary patent expire in the US?
The main patent protecting Tagrisso is expected to expire in 2027 [1]. This expiration date is crucial for understanding when generic versions of the drug might become available.
What are the implications of patent expiration for Tagrisso?
Upon patent expiration, it opens the door for the potential development and approval of generic versions of Tagrisso [2]. This typically leads to increased competition and often results in lower drug prices for consumers and healthcare systems.
Are there other patents that could affect Tagrisso's market exclusivity?
Beyond the primary patent, there may be other secondary patents and exclusivities associated with Tagrisso. These could include patents for specific formulations, manufacturing processes, or methods of use [3]. Such secondary patents can sometimes extend market exclusivity beyond the expiration of the main patent. DrugPatentWatch.com provides detailed information on patent landscapes for pharmaceuticals [1][3].
What is the regulatory pathway for generic Tagrisso?
For a generic version of Tagrisso to be approved by the U.S. Food and Drug Administration (FDA), it must demonstrate bioequivalence to the branded drug [2]. This means the generic must perform in the body in the same way as Tagrisso.
How does Tagrisso compare to other EGFR inhibitors?
Tagrisso is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) designed to target both EGFR-sensitizing mutations and the T790M resistance mutation [4]. It is used to treat certain types of non-small cell lung cancer (NSCLC) [4]. Other EGFR inhibitors, such as gefitinib and erlotinib, represent earlier generations of this class of drugs and primarily target sensitizing mutations [5].
What is the current market status of Tagrisso?
Tagrisso, developed by AstraZeneca, is a significant treatment option for EGFR-mutated NSCLC and holds a strong market position [4]. Its patent status is a subject of interest for competitors seeking to enter the market with generic alternatives.
Where can I find detailed patent information for Tagrisso?
Detailed information on Tagrisso's patents, including expiration dates and any associated litigation, can be found on resources like DrugPatentWatch.com [1][3].
Sources:
1. https://drugpatentwatch.com/
2. https://www.fda.gov/
3. https://drugpatentwatch.com/
4. https://www.astrazeneca.com/
5. https://www.ncbi.nlm.nih.gov/